Jensen, S. B. K. et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial. EClinicalMedicine 69, 102475 (2024).
Article PubMed PubMed Central Google Scholar
Ansari, S., Khoo, B. & Tan, T. Targeting the incretin system in obesity and type 2 diabetes mellitus. Nat. Rev. Endocrinol. https://doi.org/10.1038/s41574-024-00979-9 (2024).
Jastreboff, A. M. et al. Triple–hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New Eng. J. Med. 389, 514–526 (2023).
Article CAS PubMed Google Scholar
Jensen, S. B. K. et al. Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response, and beta cell function. Obesity 31, 977–989 (2023).
Article CAS PubMed Google Scholar
Lincoff, A. M. et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New Eng. J. of Med. 389, 2221–2232 (2023).
García-Vega, D. et al. Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network. Cardiovasc. Diabetol. 23, 1 (2024).
Article PubMed PubMed Central Google Scholar
Ashcroft, S. P., Stocks, B., Egan, B. & Zierath, J. R. Exercise induces tissue-specific adaptations to enhance cardiometabolic health. Cell Metab. 36, 278–300 (2024).
Article CAS PubMed Google Scholar
Corbin, K. D. et al. Glucagon-like peptide-1/glucagon receptor agonism associates with reduced metabolic adaptation and higher fat oxidation: A randomized trial. Obesity 31, 350–362 (2023).
Article CAS PubMed Google Scholar
Melson, E., Ashraf, U., Papamargaritis, D. & Davies, M. J. What is the pipeline for future medications for obesity? Int. J. Obes. https://doi.org/10.1038/s41366-024-01473-y (2024).
Herrou, J. et al. Narrative review of effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity. Calcif. Tissue Int. 114, 86–97 (2024).
留言 (0)